NAD+ and NR: When Marketing Outruns the Evidence
IV NAD+ for addiction detox. “92.5% absorption” strips. Blood-NAD+ tests sold as mitochondrial readouts. We track where NAD+ marketing parts company with human evidence — and who profits from the gap.
The October 2025 advertising ruling
The National Advertising Division’s Reus Research (Cata-Kor) decision is the clearest regulatory signal in the category: no human clinical studies on orally ingested NAD+, “liposomal or otherwise,” and “no evidence in the record” for the challenged health claims — which Reus was told to discontinue. The challenge was filed by competitor Niagen Biosciences, part of ChromaDex. That is a commercially interested process, but the evidentiary finding stands regardless of who brought it.
The June 2026 NARB appeal decision
The dispute later ran in the opposite direction. On appeal of NAD Case #7487, the National Advertising Review Board affirmed that Niagen should discontinue or modify several Tru Niagen claims. The panel found that the clinical studies did not support specified NAD+ increases as “clinically proven” for the general population, and that some heart, brain, immune, muscle and energy messages implied perceptible benefits beyond the cell-level mechanisms established by the evidence. Niagen disputed that interpretation. The decision did not dispute that NR raises blood NAD+ or that NAD+ is biologically essential; it drew the line at translating those facts into functional health or mitochondrial-performance promises without adequate clinical support. The case was brought by competitor Reus Research, now Cata-Kor, so commercial interests operated on both sides.
Addiction and detox clinics
IV NAD+ is marketed for addiction withdrawal and “detox.” A 2019 NPR/KHN investigation found these claims rest on an unpublished, uncontrolled, non-peer-reviewed pilot claiming about 90% reduced cravings — with no placebo comparison or rigorous peer review. Addiction psychiatrists called the claims unsupported. It is a classic seller-as-source loop: the clinic selling the infusions, Springfield Wellness Center, is also the source of the efficacy claims.
The absorption-number game
“92.5% absorption” dissolving strips: the number traces to advertising validated on glutathione, not NAD+ — ingredient substitution in ad copy. Liposomal NAD+ products cite plasma-pharmacokinetic papers that measured only blood exposure, then market cellular and clinical benefits the papers never tested.
Blood-NAD+ tests sold as mitochondrial readouts
Consumer “NAD+ level” tests are marketed as windows into mitochondrial health. But blood NAD+ is a labile, handling-sensitive metabolite; the 2026 Nature Metabolism study showed that freezing and thawing substantially distorts results. Whole-blood NAD+ does not track age, and it is not a proxy for tissue or mitochondrial NAD+. A blood NAD+ number is not a mitochondrial-health score.
Seller-as-source loops
Restore Hyper Wellness — a commercial IV clinic operator — employed all authors of the 2026 real-world IV NAD+/IV NR pilot. ChromaDex funds NR efficacy trials, authored the company preprint comparing IV NR favorably with IV NAD+, and funded the market-surveillance report attacking direct-NAD+ competitors’ label accuracy. Treat the company’s claims in both directions as commercially interested; the quality concern it flags is still worth independent testing.
Elysium Health sells NR/NMN products while publishing content concluding oral precursors are the “only clinically proven method” of raising cellular NAD+ — accurate on the pharmacokinetics, self-serving as a conclusion — while its own content acknowledges IV addiction claims lack human evidence. In the patent wars, ChromaDex’s key composition patent on isolated NR was invalidated by the Federal Circuit in February 2023 as a natural phenomenon under §101; its multi-year litigation with Elysium continues. Two NADPARK authors filed a patent application on NR use in Parkinson’s, a commercial interest in a small phase-I trial’s positive read. Affiliate and review sites repeat energy, detox, “cellular repair” and anti-aging claims with no direct mitochondrial measurements behind them.
Where the line is
NR’s genuine pharmacokinetic evidence deserves fair credit — it reliably raises blood NAD+ metabolites in humans. The story of this category is the gap between that biomarker and mitochondrial function, which human trials have not shown. Our standing rule: here is exactly what the human evidence supports, and where the line is.